Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
Сибирский Научный Медицинский Журнал · August 30, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing the mechanisms, applications, and challenges of CRISPR/Cas9 technology in oncology. It discusses theoretical potential in tumor suppression, CAR-T enhancement, and resistance prevention, but does not report quantitative efficacy data, clinical trials, or outcomes to support practice change.
Journal article. Patients with hematologic malignancies, breast cancer, colorectal cancer, gastric cancer, and lung cancer (potential application population, not empirically studied in this source).
CRISPR/Cas operates through three key stages—adaptation, expression, and interference—offering high precision in genetic modification Genome editing has demonstrated significant effectiveness in suppressing tumor growth and enhancing cellular sensitivity to therapy in hematologic malignancies, breast, colorectal, gastric, and lung cancers CRISPR/Cas enhances the efficacy of Chimeric Antigen Receptor T-cell Therapy (CAR-T) and helps overcome tumor cell resistance to treatment
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review should be read as an overview of CRISPR's theoretical promise in oncology and current barriers, not as evidence that any specific CRISPR-based therapy is ready for clinical use. Clinicians should await rigorous trial data before integrating CRISPR approaches into practice.
A narrative review article that synthesizes mechanistic understanding and preclinical applications of CRISPR/Cas9 in oncology without reporting primary empirical findings, efficacy data, or clinical outcomes.
This review should be read as an overview of CRISPR's theoretical promise in oncology and current barriers, not as evidence that any specific CRISPR-based therapy is ready for clinical use. Clinicians should await rigorous trial data before integrating CRISPR approaches into practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is a cutting-edge genome editing tool based on the adaptive immune mechanism of prokaryotes. This system, which operates through three key stages‒adaptation, expression, and interference‒offers high precision and efficiency in genetic modification. This article explores the mechanisms of CRISPR/Cas action and its applications in hematologic malignancies, breast cancer, colorectal cancer, gastric cancer, and lung cancer. Genome editing has demonstrated significant effectiveness in suppressing tumor growth, enhancing cellular sensitivity to therapy, and developing personalized treatment approaches. CRISPR/Cas enhances the efficacy of Chimeric Antigen Receptor T-cell Therapy (CAR-T) and helps overcome tumor cell resistance to treatment. The technology is also actively utilized in genetic screening to identify gene functions and discover new therapeutic targets. However, several challenges remain, including off-target effects, immune responses, and difficulties in delivering CRISPR components to target cells. This article discusses promising strategies to overcome these limitations, such as the development of novel Cas protein variants, improved delivery methods, and epigenetic approaches. CRISPR/Cas represents one of the most promising tools in molecular biology, providing the ability to precisely investigate gene functions and to develop new experimental strategies for therapeutic intervention. The potential of this technology is defined by its flexibility and applicability across a wide range of tasks‒including target validation, disease modeling, and the generation of advanced cellular products. However, its full integration into clinical practice requires further studies aimed at improving safety, reducing the frequency of unintended effects, and developing reliable delivery systems.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.